Loading clinical trials...
Loading clinical trials...
Open-Label Study Evaluating the Safety and Effectiveness of Immunopheresis With the LW-02 Column Alone or in Combination With Paclitaxel or Atezolizumab in Removing Soluble Tumor Necrosis Factor Receptors to Treat Patients With Advanced, Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
LW-02 device immunopheresis combined with atezolizumab
LW-02 device immunopheresis combined with weekly paclitaxel
+1 more
Locations
3
Turkey (Türkiye)
Acibadem Atakent Hospital, Medical Oncology Department
Istanbul, Kucukcekmece, Turkey (Türkiye)
Acibadem Maslak Hospital, Medical Oncology Department - coordinating site
Istanbul, Sariyer, Turkey (Türkiye)
Acibadem Altunizade Hospital, Mecical Oncology Department
Istanbul, Uskudar, Turkey (Türkiye)
Start Date
October 1, 2020
Primary Completion Date
August 31, 2022
Completion Date
December 31, 2022
Last Updated
March 8, 2022
NCT05671510
NCT03340506
NCT06066138
NCT07485114
NCT05098132
NCT04977453
Adam Ostrowski, MD Medical Director, International - Immunicom, Inc.
CONTACT
+48 606446610adam.ostrowski@immunicom.comRobert Segal, MD FACP Chief Medical Officer - Immunicom, Inc.
CONTACT
+1 2672377576robert.segal@immunicom.comLead Sponsor
Immunicom Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions